Filing summary
Entity and period: The supplied filing is Eyenovia, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, signed April 2, 2018. This does not match the request metadata identifying Hyperion DeFi, Inc. or “2017 Q4.” The filing reports annual results, not standalone fourth-quarter results.
Business context
Eyenovia is a clinical-stage ophthalmology biopharmaceutical company developing drug-delivery products using its patented piezo-print technology. Its candidates aim to deliver 6–8 microliters to the eye, compared with conventional drops of approximately 30–50 microliters. The company had no approved products, product-sale revenue, or established commercial organization at year-end.
- MicroProst: latanoprost candidate for chronic angle-closure glaucoma (CACG).
- MicroStat: fixed-combination phenylephrine/tropicamide candidate for pupil dilation.
- MicroTears: over-the-counter artificial-tear candidate.
- MicroPine: atropine candidate intended to slow myopia progression.
Financial performance and position
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $3.82 million | $2.97 million |
| General and administrative expense | $1.32 million | $0.57 million |
| Total operating expenses | $5.13 million | $3.53 million |
| Net loss | $5.13 million | $3.53 million |
| Net loss per share, basic and diluted | $2.19 | $1.56 |
| Net cash used in operations | $4.73 million | $3.20 million |
At December 31, 2017, cash was $5.25 million, current assets $5.29 million, current liabilities $0.55 million, and working capital $4.73 million. Total assets were $5.64 million, total liabilities $0.55 million, and stockholders’ equity $5.09 million. The company reported no debt outstanding at year-end. Profitability and operating margins are not meaningful because it had no product revenue and recorded operating losses.
R&D expense increased 29%, primarily from greater contracted services and headcount; G&A increased 131%, largely due to professional fees, stock compensation, travel, and IPO preparation. Net loss widened by approximately $1.60 million. Financing cash flow was $6.60 million in 2017, mainly from Series B preferred stock and warrant proceeds, versus $4.14 million in 2016 from Series A-2 preferred stock.
Liquidity, outlook, and material developments
- After year-end, the company completed its January 2018 IPO, issuing 2.73 million shares at $10 per share and receiving approximately $24.5 million in net proceeds. All outstanding preferred shares converted into common stock at the IPO closing.
- Management expected available cash to fund operating and capital requirements for at least 15 months from the filing/financial-statement issuance date; it expected to need further capital thereafter. The company warned that a funding shortfall could force it to curtail R&D or reduce costs.
- Management planned to initiate Phase III programs for MicroProst and MicroStat in the second half of 2018, subject to IND submissions and FDA feedback. Each program was expected to include two randomized trials. MicroTears registration activities and manufacturing scale-up were planned, with anticipated market introduction in 2019; MicroPine Phase III initiation was expected in 2019.
- These dates and market opportunities are management expectations, not assured outcomes. All candidates remain subject to clinical, regulatory, manufacturing, financing, and commercialization risks.
- The company licensed Asian development and commercial rights to Senju Pharmaceuticals. The agreement provides for royalties generally at 5% of net sales, subject to stated terms; no product royalties had been earned by the filing date.
Risks, contingencies, and unusual items
- Internal controls: Management concluded disclosure controls were not effective at the reasonable-assurance level at December 31, 2017 and identified material weaknesses involving segregation of duties, related-party identification, communication of agreement terms to the board, and R&D expense recording. Management described remediation plans; effectiveness was not yet established.
- Litigation: A Corinthian Ophthalmic shareholder sought approximately $1.1 million in damages in a case involving the company’s 2014 asset purchase. Trial was scheduled for September 2018. Eyenovia said it was indemnified and cited $10 million of applicable insurance coverage; it did not record a loss contingency and did not expect a material loss.
- Related-party arrangements: The filing describes consulting, office-lease, and engineering-service arrangements involving directors, executives, or affiliated entities, including $1.16 million of 2017 R&D expense for a company owned by the VP of R&D. These merit review alongside the disclosed control weakness concerning related-party identification.
- Other risks: Continued losses and future financing needs; uncertain clinical results and FDA approvals; reliance on third-party manufacturers and clinical-service providers; patent and competition risks; reimbursement and pricing uncertainty; and potential adverse events.
- The independent auditor gave an unqualified opinion on the financial statements, but did not audit or express an opinion on internal control over financial reporting.
Most important facts to verify
- Confirm the filing identity: the source is Eyenovia’s FY 2017 10-K, not a Hyperion DeFi filing.
- Review the audited financial statements and notes for cash use, preferred-stock and IPO conversions, and the basis for management’s 15-month runway estimate.
- Check whether IND submissions, FDA feedback, and the stated MicroProst, MicroStat, MicroTears, and MicroPine milestones occurred as planned.
- Assess remediation of the four material weaknesses and whether subsequent filings report effective controls.
- Track the Corinthian litigation outcome and review the related-party arrangements, disclosures, and governance oversight.